In several other studies, FXR activation was observed to improve glucose metabolism, reverse insulin resistance and enhance insulin sensitivity, which in turn highlighted the potential of FXR agonists (i.e., bile acids and their synthetic derivatives) as therapies for metabolic syndrome, diabetes and obesity [9,10,11,12]. Here, NR1H4 is linked to obesity due to melanocortin 4 receptor deficiency.